

Tagrisso (osimertinib) Prior Authorization Request Form



LIDGENT

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			☐ OKGENI		
MEMBER INFORMATION					
LAST NAME:		FIRST NAME:			
PHONE NUMBER:		DATE OF BIRTH:			
STREET ADDRESS:					
CITY:		STATE: ZIP CO	DDE:		
PATIENT INSURANCE ID NUI	MBER:				
☐ MALE ☐ FEMALE HEIG	GHT (IN/CM): WEIG	HT (LB/KG): ALLI	ERGIES:		
IF YOU ARE NOT THE PATIENT OR THE PRESCRI					
FOLLOWING LINK: HTTPS://MAGELLANRX.CO	IM/MEMBER/EXTERNAL/COMMERCIAL/COM	/IMON/DOC/EN-US/PHI DISCLOSURE A	UTHORIZATION.PDF		
PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:					
AUTHORIZED REPRESENTATIV	VE 3 PHONE NOWIDER:				
PRESCRIBER INFORMATION		_			
LAST NAME:		FIRST NAME:			
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:			
NPI NUMBER:		DEA NUMBER:			
PHONE NUMBER:		FAX NUMBER:			
STREET ADDRESS:					
CITY:		STATE: ZIP CO	DDE:		
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:			
MEDICATION OR MEDICAL	DISPENSING INFORMATION				
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
☐ NEW THERAPY	RENEWAL	IF RENEWAL: DATE THE	RAPY INITIATED:		
DURATION OF THERAPY (SPE	ECIFIC DATES):				
Continued on next nage					

Continued on next page.





Tagrisso (osimertinib) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:		
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
☐ Primary Non-small cell lung cancer (NS		
☐ Metastatic Non-small cell lung cancer (
□ Other DiagnosisICD-10	U Code(s):	
3. REQUIRED CLINICAL INFORMATION	: PLEASE PROVIDE ALL RELEVANT CLINI	ICAL INFORMATION TO SUPPORT A
PRIOR AUTHORIZATION.		
Clinical Information:		
Is drug going to be used in conjunction	on with a clinical trial? Yes No	
Does the patient's tumor harbor an E	GFR exon 19 deletion or an exon 21 L8	58R mutation? ☐ Yes ☐ No <i>Please</i>
submit the tumor genetic analysis.		
For diagnosis of primary non-small ce	Il lung cancor answer the following.	
	?	tation.
	. = =	
Has patient undergone COMPLETE su	rgical resection of the primary NSCLC?	□ Yes □ No
Were all surgical margins of the resec	tion negative for tumor? Yes No	Please submit pathology report.
Has patient undergone radiation the	rapy? □ Yes □ No	
•	cer treatment(s)(including any chemot	therapy or any EGFR-TKI agent(s))? \Box
Yes □ No		
For diagnosis of metastatic non-small	cell lung cancer, anwer the following:	
Will Tagrisso be used as first-line?	Yes □ No	
Will Tagrisso be used with chemothe		
With Tagrisso be used without chemo	otherapy? 🗆 Yes 🗆 No	
Renewal Request:		
•	a positive clinical response? 🗆 Yes 🗀 l	No Please submit documentation.
Are there any other comments, diagnostician feels is important to this re	oses, symptoms, medications tried or fa	iled, and/or any other information the
physician reers is important to this re	v IC vv :	
-		_
Please note: Not all drugs/diagnosis an information is received	re covered on all plans. This request may	be denied unless all required

© 2017–2018 by Magellan Rx Management, LLC. All Rights Reserved.

Revision Date: 3/15/24 CAT0242

Page **2** of **3**

Caterpillar: Confidential Green







MEMBER'S LAST NAME:

Tagrisso (osimertinib) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S FIRST NAME:

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.			
Prescriber Signature or Electronic I.D. Verification: Date:	-		
CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the conte of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return F, and arrange for the return or destruction of these documents.	nts		

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811

© 2017–2018 by Magellan Rx Management, LLC. All Rights Reserved. Revision Date: 3/15/24 CAT0242

Page 3 of 3

O

